Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

Sam Chen

Associate

Nan Chen

Principal

Anna French

Partner

Jinda Gao

Executive Director

William Hu

Managing Partner

Duane Kuang

Co-Founder & Managing Partner

Grace Lee

Partner

Nisa Leung

Managing Partner

Shuo Mao

vice_president

Mark McDade

Partner

Gary Rieschel

Co-Founder & Managing Partner

Amy Tang

Venture Partner

Shiyu Wang

Partner

Bonnie Wang

Principal

Jing Wu

Partner

Kuantai Yeh

Partner

Janet Yu Ph.D

Partner

Alex Zhou

Partner

Past deals in Nanotechnology

GenEdit

Angel Round in 2021
GenEdit, Inc. focuses on the development of novel, non-viral, nanoparticle-based delivery technology and enabling next generation CRISPR-based gene therapies. The foundation of our CRISPR-Nanoparticle Technology Platform is based on successfully engineering the individual components of the CRISPR system to overcome the limitations of existing delivery vehicles for CRISPR-based therapeutics.

Newsoara

Venture Round in 2021
Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Newsoara

Series B in 2019
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
MicroPoint Bioscience, Inc. (微点生物) is a Chinese company dedicated to biochip research and development. The company offers a product series, Lab On a Chip, which is based on micro-electronic mechanical technologies. MicroPoint Biosciences customizes demanded products and services for customers in areas of human health such as medicine, environmental protection, food safety, scientific research, and other application areas. In the area of medicine, MicroPoint Company's bedside immediate diagnosis chip and examination instrument provides low-cost resolutions for early diagnosis and the process monitoring of vascular diseases, tumors, emergency treatments, and operations.

Sinocelltech

Series A in 2017
Sinocelltech Group Limited is a Beijing-based biotech company specializing in the development and manufacture of recombinant proteins, monoclonal antibodies, and vaccines. The company has established advanced platforms for protein expression vectors, cell line development, and serum-free medium development, alongside techniques for controlled fed-batch cell culture, process scale-up, and protein purification. Sinocelltech is committed to making life-saving biological medicines accessible to the general public by continuously enhancing its manufacturing processes and technologies to reduce development and production costs.

Ants Technology

Series B in 2014
Ants Technology

Ants Technology

Series A in 2014
Ants Technology